Pasireotide maintenance for synovial sarcoma and DSRCT
Part of Cancer clinical trials.
This trial tests a drug called pasireotide as a maintenance therapy (given after standard treatment to keep cancer from coming back) for people with specific types of sarcoma. It's for patients whose tumors show high levels of certain proteins (SSTR) and who have stable or better disease after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of DSRCT (any stage) or synovial sarcoma that is stage III, has spread, or has come back after treatment.
- Your tumor must have high levels of SSTR proteins (SSTR2, SSTR3, or SSTR5) as shown by a special genetic test.
- After finishing standard treatment, your disease must be stable, smaller, or gone (no active cancer growth).
- You must be between 13 and 50 years old, weigh at least 66 pounds (30 kg), and have a body surface area of at least 1.1 m².
- You must be able to do most daily activities on your own (Karnofsky or Lansky score of 80% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
This trial tests a drug called pasireotide for people with prolactinoma (a type of pituitary tumor) who cannot use standard dopamine agonist medicines or whose tumors do not shrink enough with them. It may be an option if surgery isn't right for you.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
Hear when a new Desmoplastic Small Round Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.